Oncolytics Biotech Inc. · NASDAQ:ONCY

Oncolytics Biotech — Investor Presentation (February 2015)

26 slides from Oncolytics Biotech's investor presentation, Feb 18, 2015

  1. Slide 1: Corporate Presentation

    Corporate Presentation February 18, 2015

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains certain forward looking statements relating to the company’s financial results, business prospects and the development and commercialization of REOLYSIN®, a therapeutic reovirus. These statements are based on management’s current expectations and

  3. Slide 3: Oncolytics Overview

    Oncolytics Overview o Broad Clinical Program o Lead product is REOLYSIN®, a broadly active novel cancer therapy o Ongoing clinical trials include five sponsored, randomized Phase II studies in the US and Canada o Conducted over 30 clinical studies in 13 indications to date o Strong Intellectual Prop

  4. Slide 4: Randomized Clinical Trial Program for REOLYSIN: Active Studies

    Randomized Clinical Trial Program for REOLYSIN®: Active Studies Trial Phase Sponsor n Enrollment Status IND 213: Intravenous REOLYSIN® in Combination with Paclitaxel in Patients with Advanced or Metastatic II NCIC CTG 100 >60% complete Breast Cancer IND 211: Intravenous REOLYSIN® in Combination with

  5. Slide 5: REOLYSIN Mechanism of Action

    REOLYSIN® Mechanism of Action Normal Cells REOLYSIN® REOLYSIN® Healthy cells REOLYSIN® infects both does not remain tumour cells replicate in undamaged Progeny viruses repeat cell and normal cells that are Administered to infection cycle in nearby tumour patients healthy cells not Ras cells prescree

  6. Slide 6: REO 003: REOLYSIN Intratumoural Monotherapy Anaplastic Astrocytoma

    REO 003: REOLYSIN® Intratumoural Monotherapy Anaplastic Astrocytoma Early Cytotoxic Activity Followed by Late Stage Immune-Mediated Response Against the Residual Tumour Days after REOLYSIN® administration: 0 3 43 88 167 537 Viral replication mediated Post debulking Immune mediated tumour response tu

  7. Slide 7: Ras Pathway Specific Biomarkers and Cancer

    Ras Pathway Glioblastoma EGFR, BRAF Specific Biomarkers Head & Neck EGFR and Cancer Non-Small Cell Lung EGFR, BRAF, KRAS Breast HER-2 (an EGFR variant) Pancreas KRAS Colorectal KRAS, EGFR Melanoma BRAF, S100 Biomarkers are increasingly used to assess risk, diagnose, and identify treatment options 7

  8. Slide 8: REO 016: Single-Arm NSCLC Study Demonstrates Biomarker Utility

    REO 016: Single-Arm Non-Small Cell Lung Cancer (NSCLC) Study Demonstrates Biomarker Utility Number of Number of Patients Percentage of Patients Molecular Abnormality Patients Surviving One Year Surviving One Year BRAF mutation + EGFR amplification 4 4 100% EGFR amplification 10 7 70% EGFR mutation +

  9. Slide 9: REOLYSIN: Clinical History

    REOLYSIN®: Clinical History o To date, over 1,000 patients have been treated with REOLYSIN®, which has been shown to be safe and well- tolerated o Over 30 ongoing and completed studies of REOLYSIN® in North America and Europe, examining a variety of: o Modes of administration o Therapeutic combinati

  10. Slide 10: REOLYSIN: Reducing Tumour Burden

    REOLYSIN®: Reducing Tumour Burden

  11. Slide 11: REO 011: Head & Neck Cancer Patient with Partial Response in Liver Metastases

    REO 011: Head & Neck Cancer Patient with Partial Response in Liver Metastases Pre-Treatment Post-Cycle 6 The patient had been previously been treated with radiation. The response to REOLYSIN® was maintained through 8 cycles. 11

  12. Slide 12: REO 021: Partial Response in Lung

    REO 021: Partial Response in Lung Right Upper Lung Mass (8.3 cm) Right Upper Lung Mass (4.1 cm) Right Upper Lung Mass (3.6 cm) Right Pleural Met (2.2 cm) Right Pleural Met (0.8 cm) Right Pleural Met (0.4 cm) Pre-Treatment Post-Cycle 2 Post-Cycle 4 12

  13. Slide 13: REO 016: Partial Response in Lung (EGFR Over-Expression)

    REO 016: Partial Response in Lung (EGFR Over-Expression) Pre-Treatment Post-Cycle 2 13

  14. Slide 14: REO 018 Head and Neck Cancer: Randomized Tumour-Specific Response Data

    REO 018 Head and Neck Cancer: Randomized Tumour-Specific Response Data o This study demonstrated that REOLYSIN® increases both the magnitude and velocity of tumour shrinkage o The first endpoint examined initial percentage tumour changes between baseline and first post treatment scans in all patient

  15. Slide 15: REOLYSIN: Improving Survival (PFS & OS)

    REOLYSIN®: Improving Survival (PFS & OS)

  16. Slide 16: Randomized Top-Line Survival Data

    Randomized Top-Line Survival Data REO 018 (Head and Neck Cancer): o An analysis of patients with loco-regional disease with or without distal metastases showed a median PFS of 94 days (13.4 weeks) in the test arm (n=62), versus a PFS of 50 days (7.1 weeks) in the control arm (n=56) o Patients who re

  17. Slide 17: Enhancing Immune Responses to Improve Survival

    Enhancing Immune Responses to Improve Survival o Ongoing preclinical research has led to two clinical candidate programs: 1. GM-CSF in combination with REOLYSIN®; or 2. A checkpoint inhibitor in combination with REOLYSIN® 21

  18. Slide 18: GM-CSF + REOLYSIN: Effect on Overall Survival

    GM-CSF + REOLYSIN®: Effect on Overall Survival 100 IL2 + REO IL2 alone 80 G-CSF + REO Percent Survival G-CSF alone 60 GM-CSF + REO GM-CSF 40 20 0 0 20 40 60 Days 22

  19. Slide 19: REOLYSIN + Anti-PD-1: Effect on Overall Survival

    REOLYSIN® + Anti-PD-1: Effect on Overall Survival 23

  20. Slide 20: Possible Registration Pathways for REOLYSIN

    Possible Registration Pathways for REOLYSIN® I. Studies using REOLYSIN® therapy prior to standard efficacy- based therapies (surgery, radical radiotherapy and chemotherapy) in order to reduce tumour burden, as measured by histopathology, scans, or tumour specific markers; and/or II. Studies using RE

  21. Slide 21: REOLYSIN and Safety

    REOLYSIN® and Safety o More than 1,000 patients treated, more than 900 intravenously at doses up to 3x1010 TCID50 daily o No maximum tolerated dose (MTD) reached to date o Monotherapy toxicities have generally been mild (Grade 1 or 2) and included chills, fever, headache, cough, myalgia, runny nose,

  22. Slide 22: Intellectual Property

    Intellectual Property o More than 370 patents issued worldwide, including 56 US and 20 Canadian o Reovirus issue patent claims cover: o Compositions of matter comprising reovirus o Pharmaceutical use of reoviruses to treat neoplasia and cellular proliferative diseases o Combination therapy with radi

  23. Slide 23: Manufacturing

    Manufacturing o Now produced at 100L (commercial scale) under cGMP with final formulation o Commercial manufacturing agreement in place with Sigma- Aldrich® Fine Chemicals (SAFC) 23

  24. Slide 24: Market & Capital Data

    Market & Capital Data (all amounts in CAD) Exchanges NASDAQ:ONCY TSX:ONC Shares Outstanding (September 89,566,597 30, 2014) Price Options Outstanding (September $3.49 (weighted 5,987,844 30, 2014) average) Fully Diluted (September 30, 2014) 96,410,358 Cash/Cash Equivalents $17.04M (September 30, 201

  25. Slide 25: Investment Highlights

    Investment Highlights o Five ongoing randomized Phase II studies, with data readouts anticipated in 2015 o Indications: ovarian, colorectal, non-small cell lung, prostate and breast cancers o Preparing for registration study o Safety data for 1,000+ patients o Strong intellectual property portfolio

  26. Slide 26: Corporate Presentation

    Corporate Presentation February 18, 2015

Oncolytics Biotech — Investor Presentation (February 2015) on 6ix